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Abstract 
Objective: Ventricular enlargement (VE) is common in established 
schizophrenia, however, data from ultra high-risk for psychosis (UHR) and 
first episode psychosis (FEP) studies are inconclusive. This study aims to 
investigate ventricular volumes at different stages of psychosis. 
Methods: Ventricular volumes were measured using a semi-automated and 
highly reliable method, for 89 established schizophrenia, 162 FEP, 135 UHR 
and 87 healthy controls using 1.5T magnetic resonance images. Clinical 
outcome diagnoses for UHR were evaluated at long-term follow-up (mean 7.5 
years).  
Results: Compared to controls we identified significant VE of 36.2% in 
established schizophrenia (p<.001). VE was not significant in FEP (6%) or 
UHR (-3%). Examination across stages of schizophrenia spectrum diagnoses 
subgroups revealed a significant linear trend (p=.006; established 
schizophrenia = 36.2%; FEP schizophrenia = 18.5%; FEP schizophreniform = 
-4.2%; UHR-schizophrenia converters = -18.5%).  
Conclusions: VE is apparent in patients with established schizophrenia but is 
not a feature at the earliest stages of illness (UHR and FEP). Further research 
is needed to fully characterise the nature and timing of ventricular volume 
changes early in the course of illness and how these changes impact on 
outcomes.  
Key Words: Ventricle, First Episode Psychosis, Ultra High Risk, Diagnosis, 
Neuroimaging 
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INTRODUCTION 
Ventricular enlargement (VE) is one of the most reproducible and 
recognizable structural abnormalities in established schizophrenia (2005; 
Kempton et al., 2010), and is associated with poorer clinical outcomes, more 
negative symptoms and cognitive decline (Cahn et al., 2006). Cross-sectional 
meta-analyses involving substantial numbers of drug-naïve patients (Wright et 
al., 2000; Haijma et al., 2012; van Erp et al., 2016) provide robust evidence 
for VE. Recently, three systematic reviews of longitudinal brain imaging 
studies confirmed significant progressive VE in established schizophrenia 
(Kempton et al., 2010; Olabi et al., 2011; Fusar-Poli et al., 2013), at roughly 
two to four times that seen in normal brain development (Olabi et al., 2011). 
However, our understanding of when and how these changes occur is limited. 
Meta-analytic results for first episode schizophrenia and other psychotic 
disorders point towards VE also being present early on in the illness (Vita et 
al., 2006; De Peri et al., 2012; Steen et al., 2006), although some studies, 
including a meta-analysis and several longitudinal studies, have conversely 
found no significant difference in ventricular volumes (VV) of FEP patients 
compared with controls (Kempton et al., 2010; Boonstra et al., 2011; Ayesa-
Arriola et al., 2013; Chakos et al., 1994). 
Studies investigating VE in pre-psychotic individuals are scarce. Those 
that have focused on genetic high-risk populations have mainly failed to find 
significant differences when compared to healthy controls (HC; Cannon et al., 
1998; Lawrie et al., 1999; Lawrie et al., 2001; Lawrie et al., 2002). Only one 
study in adolescents with one or both parents diagnosed with schizophrenia, 
Ventricle volumes in emerging psychotic disorders Berger G, et al. 
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found significant VE in comparison to HC, with more pronounced 
enlargements for those with greater genetic risk (Cannon et al., 1993). An 
alternative high-risk strategy is to identify a help-seeking group using the ‘ultra 
high-risk’ (UHR) approach (Yung et al., 2004), representing a clinical sample 
with a high conversion rate to psychosis of about 20-30% over 12-24 months 
(Fusar-Poli et al., 2012). This approach integrates three subgroups: an 
attenuated symptoms group, a group with brief self-limiting psychotic 
episodes (BLIPS) and a genetic liability group experiencing functional decline 
(Yung et al., 2004; Nelson et al., 2013). Because UHR individuals are 
clinically unwell and in need of treatment, they theoretically sit in between the 
genetic high-risk (or at-risk/mildly unwell) and FEP stage, according to the 
clinical staging model (McGorry et al., 2007). To our knowledge, only two 
research groups have used this UHR approach to examine VE in emerging 
psychosis (Ziermans et al., 2009; Ziermans et al., 2012; Cannon et al., 2015), 
and both have failed to find cross-sectional group differences in mean VVs at 
study entry, not only between the UHR group and controls but also between 
controls, UHR converters (UHR-P; those who go on to develop a psychotic 
disorder) and non-converters (UHR-NP).  
In the current cross-sectional study, we investigated VV in large groups 
of individuals who were in different stages of psychotic illness, including UHR, 
first episode psychosis (FEP) and established schizophrenia (Est-SZ). We 
predicted that VE between groups would increase by illness stage, and that 
greater duration of illness would be associated with greater VE.  
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METHOD 
Participants 
Participants were scanned between 8th July 1994 and 4th May 2001, 
representing the same cohort examined in an earlier study of hippocampal 
and amygdala volume (Velakoulis et al., 2006). Given the sample 
characteristics and ascertainment strategy has been described previously in 
detail, we will only briefly outline the methodology here. Exclusion criteria 
were a history of substantial head injury, seizures, neurological diseases, 
impaired thyroid function, corticosteroid use or DSM-III-R criteria of alcohol or 
substance abuse or dependence. HC with a personal or family history of 
psychiatric illness were excluded. The local research and ethics committees 
approved the study and the collation of data collected from across several 
studies.  Written informed consent was obtained from all subjects; for minors 
consent was also obtained from a parent/guardian. 
510 subjects were initially recruited, of which 37 were subsequently 
excluded due to findings of an unsuspected brain lesion (incidental finding, 
n=12), diagnosis revision (n=12) or insufficient data (n=13). Table 1 shows the 
sex, age and height of the remaining 473 participants included in the final 
analysis.  
 
----------Insert Table 1 approx. here---------- 
 
89 Est-SZ patients (76 males, 13 females; mean age 34.9 ± 9.6 years) 
were recruited from the Adult Mental Health Rehabilitation services of the 
North Western Mental Health Program. Established SZ was defined as those 
Ventricle volumes in emerging psychotic disorders Berger G, et al. 
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who had more than 18 months of continuous illness. The median illness 
duration was 12 years (range 2-46 years). 
 162 FEP patients (108 males, 54 females; mean age 21.5 ± 3.4 years) 
were recruited from the Early Psychosis Prevention and Intervention Centre 
(EPPIC), Melbourne, Australia, and as such met EPPIC intake criteria 
(McGorry et al., 1996). The inclusion criteria for FEP to the current study were 
a) age 15 to 30 years, and b) currently psychotic as determined by the 
presence of at least one of the following symptoms: hallucinations, delusions, 
disorder of thinking or speech, or disorganized, bizarre or markedly 
inappropriate behavior (Velakoulis et al., 1999). FEP participants were divided 
into 4 subgroups: 1) first-episode schizophrenia (FE-SZ; n=46, including first-
episode schizoaffective disorder), 2) first-episode schizophreniform 
psychoses (FE-SZform; n=57), 3) affective psychoses (n=34, including bipolar 
and major depressive disorders with psychotic features), and 4) other 
psychoses (n=25).  
 135 UHR subjects (78 males, 57 females; mean age 20.1 ± 3.6 years) 
who had not experienced a previous psychotic episode and were aged 14-30 
years, were recruited from the Personal Assessment and Crisis Evaluation 
(PACE) Clinic, Orygen Youth Health, Melbourne (Yung et al., 1996; Phillips et 
al., 2002). All UHR participants were required to meet Comprehensive 
Assessment of At Risk Mental States (CAARMS) criteria (Yung et al., 2005). 
Of note, there were minor changes to the UHR criteria from 1993 to 1995, 
when UHR group 3 (trait plus state risk factors) omitted the second-degree 
relative criterion and operationalized the required decline in functioning. 
Further, from 1993 to 1999, while the concurrent validity of the CAARMS was 
being established, psychosis threshold was determined using both the Brief 
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Psychiatric Rating Scale/Comprehensive Assessment of Symptoms and 
History as well as the CAARMS (for further details see Nelson et al., 2013). 
As part of the current research protocol, all UHR participants were monitored 
for the onset of psychotic symptoms for at least 12 months. All UHR 
individuals were again assessed on average 7.5 years later (SD, 3.2; range, 
2.4-14.9 years after presentation to the clinic) as part of a larger study (Nelson 
et al., 2013). UHR converters were defied as those individuals who at any 
time during the follow-up period went on to develop a psychotic disorder 
(termed UHR-P), and non-converters were those who never experienced full-
threshold psychosis during the follow-up period (termed UHR-NP). Based on 
CAARMS criteria for psychosis threshold, 52 UHR patients developed 
psychosis (UHR-P; 39 during the initial short-term follow-up and another 13 
during the long-term follow-up) while 83 did not (UHR-NP). Two UHR 
participants were deemed to have transitioned based on the CAARMS, 
however their psychotic diagnosis (based on DSM-IV) was unknown, thus 
they were excluded from analyses related to diagnostic subgroups (see data 
analyses section). For certain analyses, the UHR-P group were further divided 
into UHR individuals who later converted and were given a diagnosis of 
schizophrenia (UHR-SZ) and UHR individuals who converted and were given 
a schizophrenia-spectrum diagnosis other than schizophrenia (UHR other 
psychosis).    
 87 HC (55 males, 32 females; mean age 26.9 ± 10.1 years) from a 
similar demographic region (i.e. greater metropolitan area of Melbourne)  as 
the patients, were recruited through auxiliary hospital staff and 
advertisements. 
 Psychopathology in the Est-SZ and FEP participants was measured 
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using the Positive and Negative Syndrome Scale (Kay et al., 1987), while the 
Brief Psychiatric Rating Scale (Overall and Gorham, 1962) and the Scale for 
the Assessment of Negative Symptoms (Andreasen, 1982) were used to 
assess psychopathology in the UHR participants. Other clinical information 
including handedness, date of illness onset (where available), estimated pre-
morbid IQ (where available) as assessed by the National Adult Reading Test 
(NART; Nelson and Willison, 1991), and medication data was obtained from 
patient interview and detailed chart review.  
 A total of 226 patients were treated with antipsychotic medication: 72 
were treated with typical antipsychotic medication (31 Est-SZ [34.8%]; 41 FEP 
[25.3%]); 109 were treated with atypical antipsychotic medication other than 
clozapine (4 Est-SZ [4.5%]; 105 FEP [64.8%]); 32 patients were treated with 
clozapine (28 Est-SZ [31.5%]; 4 FEP [2.5%]); 4 patients were treated with 
typical and atypical antipsychotic medications concurrently (4 Est-SZ [4.5%]; 0 
FEP); 9 patients were not prescribed any antipsychotic medication (2 SZ 
[2.9%]; 7 FEP [4.3%]); 25 had no medical data available (20 Est-SZ; 5 FEP). 
Mean chlorpromazine equivalent dose for the Est-SZ and FEP groups were 
845.7 mg/day (SD=696.4) and 219.4 mg/day (SD=133.6) respectively.  
MRI acquisition 
All Est-SZ, FEP and HC were scanned at the Royal Melbourne 
Hospital with the same instrument (1.5T Signa; General Electric Medical 
Systems, Milwaukee, Wisconsin). The UHR participants underwent MRI at 2 
separate locations (52 participants at the Royal Melbourne Hospital and 83 at 
the Royal Children’s Hospital, Melbourne) using identical scanners (1.5T 
Signa). All participants were scanned with identical sequences (a 3-
Ventricle volumes in emerging psychotic disorders Berger G, et al. 
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dimensional volumetric spoiled-gradient recalled echo: 3D-SPGR). 
Comparison of intracranial volumes (ICVs) for scans at the 2 sites for the 
UHR sample did not show a significant effect of MRI site (F(1,133)=0.03; 
p=.86). Similarly, there was no significant difference in ICV-corrected VV 
(cVV; see statistical analysis for correction method) between the two UHR 
subgroups who were scanned at different sites (F(1,133)=1.65, p=0.20). Note 
that, age and sex were not used as covariates as there were no significant 
difference between the two UHR subgroups (p=.30 and .28 respectively). 
(See supplementary material for graphical description of cVV distributions of 
UHR participants by scan-site).        
Each scanner was calibrated fortnightly using the same proprietary 
phantom to ensure stability and accuracy of measurements over the period of 
data collection. Calibration was in accordance with the respective hospitals’ 
and manufacturer’s operating procedures. A three-dimensional volumetric 
spoiled-gradient recalled echo in the steady-state sequence generated 124 
contiguous, 1.5mm coronal sections. Imaging parameters were as follows: 
echo time TE = 3.3 milliseconds; repetition time TR = 14.3 milliseconds; flip 
angle = 30°; matrix size = 256 X 256; FOV = 24 x 24 cm2 matrix; and voxel 
dimensions = 0.938 X 0.938 X 1.5mm3. ANALYZE 7.5 (Mayo) and MRICRO 
(http://www.mccauslandcenter.sc.edu/mricro/) were used to estimate 
volumes. 
Intracranial Volumes (ICV): ICV was estimated from a sagittal reformat 
of the original 3D dataset (Eritaia et al., 2000). The major anatomical 
boundary was the dura mater. The cerebral contour was traced where the 
dura mater was not visible.  Other landmarks were the undersurfaces of the 
frontal lobe, the dorsum sellae, the clivus and at the craniovertebral junction, 
Ventricle volumes in emerging psychotic disorders Berger G, et al. 
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the attachment of the dura to the anterior cutting across to the posterior arch 
of the C1 vertebra. Inter- and intra-rater ICC measurements were both 0.99 
for 10 randomly selected volumes. 
Ventricular Volumes (VVs): The volumes of lateral ventricles included 
the cornu frontale, the pars centralis, the cornu occipitale and the cornu 
temporale (without the third and fourth ventricle) and were estimated using a 
semi-automated method, using MRICRO. A seed was first placed at one spot 
within the ventricle and the intensity threshold was adjusted to grow the seed 
so that it filled the ventricle maximally.  Further seeds were placed in other 
parts of the ventricle as required to fill the entire ventricle. The extracted 
voxels were saved as a binary object, and then quantified using ANALYZE. 
Inter- and intra-rater reliabilities were assessed using intra-class correlation 
coefficients (ICCs); and were 0.9740 and 0.9634, respectively. 
Statistical analyses 
Demographic data between HC, UHR, FEP and Est-SZ were 
compared using chi-square analyses for sex, 1-way analyses of variance 
(ANOVA) for age, height (a proxy for head size) and NART predicted 
premorbid IQ (using the Tukey test for post hoc comparisons) and univariate 
analysis of co-variance (ANCOVA), co-varying for age and sex (using the 
Sidak test for post hoc comparisons).  
ICV was compared between groups using a univariate ANCOVA, with 
height as a covariate. Ventricular volumes (VV) were log-transformed to 
obtain a normal distribution and corrected for ICV using a previously 
described formula (Free et al., 1995): corrected VV (cVV) = measured VV – k 
(measured ICV – mean ICV of control group); where k = gradient of the 
Ventricle volumes in emerging psychotic disorders Berger G, et al. 
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regression line between ventricular volume and ICV in control participants. 
These corrected values were then used for analyses (described below), which 
all included sex and age as covariates. 
Four sets of univariate ANCOVAs were performed to investigate our 
hypotheses (within each analysis, patient groups were compared with HC): 
Analysis 1: Comparison of Est-SZ, FEP, UHR; Analysis 2: Comparison of FEP 
subgroups (first episode schizophrenia (FE-SZ), schizophreniform disorder 
(FEP-SZform), affective disorder, other psychoses); Analysis 3: Comparison 
of FEP (all), UHR-P, UHR-NP; and Analysis 4: UHR who developed 
schizophrenia (UHR-SZ) versus UHR who developed other psychotic 
disorders.  
For univariate ANCOVAs that revealed significant group effects, these 
analyses were re-run with pairwise comparisons, based on estimated 
marginal means with Bonferroni correction, which served as post hoc 
contrasts (Partial Eta2 effect sizes are reported, plus 95% confidence 
intervals). In addition, based on the pattern of results from the above-
mentioned analyses, a post hoc cross-sectional linear trend analysis 
comparing across illness stages, using a univariate ANCOVA with pairwise 
comparisons, was performed for the schizophrenia diagnoses subgroups (i.e. 
Est-SZ, FE-SZ, FEP-SZform, UHR-SZ; and 95% confidence intervals of the 
log cVV will also be reported for these pairwise comparisons). 
Antipsychotic medication: A univariate ANCOVA was conducted with 
sex and age as covariates to compare (log transformed) cVV among different 
classes of medication (typical, atypical, clozapine, nil) for the Est-SZ and FEP 
groups combine, in comparison to healthy controls. The 4 participants who 
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were taking a combination of both typical and atypical antipsychotic 
medications were excluded from this analysis. Furthermore, while comparison 
of cVV between Est-SZ and FEP participants by medication class is difficult 
given the uneven and in some instances small numbers in each subgroup, we 
nonetheless ran a univariate ANCOVA to examine whether the relationship 
between medication class and cVV differed between these two patient 
groups.  
To explore possible effects of antipsychotic medication dosage, we 
conducted partial correlations using cVV and CPZ-Eq (controlling for illness 
duration) for the Est-SZ and FEP groups separately. 
Because no UHR participant was prescribed antipsychotic medication 
at the time of MRI scanning, this group was not included in this comparison.    
   
Correlational analysis: Partial correlations, controlling for age and sex, 
were used to determine the relationship between (log transformed) cVV and 
duration of illness (DOI) for Est-SZ and FEP participants.  
  
RESULTS 
Sample characteristics 
Investigation of demographic variables revealed significant group 
differences for age (F(3,469) =109.627; P<.001; mean age in years: Est-SZ 
34.9, HC 26.9, FEP 21.5, and UHR 20.1), sex (Chi-Square = 19.4; P<.001; 
percentage of males: SZ 85.4%, FEP 66.7%, HC 63.2% and UHR 57.8%) and 
height (F(3,458)=4.223; P=.006; HC>Est-SZ>FEP>UHR) (see Table 1). 
Ventricle volumes in emerging psychotic disorders Berger G, et al. 
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NART predicted premorbid IQ was also significantly different between groups 
(F(3,368) = 7.18, p<.001; HC>UHR>FEP>SZ), which was significant for the 
Est-SZ (p<.001) and FEP (p=.004) groups when compared to controls. There 
was no significant ICV difference found between Est-SZ, FEP, UHR and HC 
groups (p=.103). Levels of overall psychopathology were the following for 
each patient group respectively: UHR (N=97; BPRS M=18.59, SD=7.09; 
SANS M= 23.37, SD=15.74), FEP (N=131; PANSS M=85.43, SD=17.73) and 
Est-SZ (N=47; PANSS M=91.06, SD= 24.59). T-test showed no significant 
difference in total PANSS score between the FEP and Est-SZ groups 
(t(176)=1.68 , p=.095). 
 
Analysis of Ventricular Volumes 
Comparison of cVVs between the three main groups revealed a 
significant group effect (Analysis 1: F(3,467)=7.165; p<.001; Table 2; Figure 
1). Post-hoc pairwise comparisons found 36.2% larger cVVs in Est-SZ 
compared to HC (p<.001). In contrast, there were no statistically significant 
group differences in cVV for the FEP (6.0% difference; p=.687), or UHR group 
(-3.0% difference; p>.99) when compared to HC participants.  
 
---------- Insert Table 2 & Figure 1 about here ---------- 
 
Comparison of cVVs within FEP diagnostic subgroups revealed no 
significant group effect (Analysis 2: F(4,242) =1.710; p=.148), although the 
FE-SZ group displayed cVVs that were 18.5% larger than controls. The 
percentage difference in cVVs for each of the patient groups in comparison to 
Ventricle volumes in emerging psychotic disorders Berger G, et al. 
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HC is shown in Table 2 and Figure 2. In summary, compared with HC, lateral 
cVVs were significantly enlarged in the Est-SZ group, but not in first-episode 
schizophrenia, first-episode schizophreniform disorder, other first-episode 
psychosis, UHR-P or UHR-NP groups. 
Comparison of cVVs between HC, FEP, UHR-P and UHR-NP revealed 
no significant group effect (Analysis 3: F(3,378)= 1.109; p=.345; see Table 2). 
Direct comparison of cVVs between UHR who were later diagnosed with 
schizophrenia and UHR who were later diagnosed with another psychotic 
disorder did not reveal any significant group effect (Analysis 4: (F(2,132) 
=1.109; p= .307; see Table 2). 
 
------------------------- Insert Figure 2 about here ------------------------ 
 
Trend analysis of schizophrenia subgroups 
Examination of cVV for the schizophrenia subgroups across stages of 
illness (i.e. Est-SZ, FE-SZ, FEP-SZform, UHR-SZ) revealed a significant 
linear trend from UHR to chronic schizophrenia, whereby cVVs increased with 
each schizophrenia illness stage (F(3,212)= 4.26, p=.006; see Table 2 and 
Figure 2). Pairwise comparisons showed that the Est-SZ group displayed 
significantly larger cVV in comparison to FEP-SZform (p=.006; CIs= .040, 
.233) and UHR-SZ (p=.003; CIs= .062, .301). Further, the FE-SZ group 
displayed significant VE relative to UHR-SZ subgroup (p=.018; CIs= .023, 
.236), and VE approached significance in comparison to the FEP-SZform 
subgroup (p=.053; CIs= -.001, .170). 
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Effects of class of antipsychotic medication 
Overall, the univariate ANCOVA revealed a significant effect of class of 
medication on cVV (F(4,302) =5.535; p<.001). Post hoc pairwise comparisons 
showed that psychotic patients (both Est-SZ and FEP pooled) prescribed 
typical antipsychotics (p=.005) or clozapine (p=.001) had significantly larger 
cVVs than the HC group. In addition, the clozapine treated participants 
displayed VE in comparison to participants prescribed other atypical 
antipsychotic medications (p=.035). Univariate ANCOVA comparing cVV of 
Est-Sz and FEP patients showed that there was no group by medication class 
interaction (p=.489). Partial correlations between cVV and CPZ-Eq did not 
reveal any significant relationship for either the Est-SZ (p=.095) or FEP 
(p=.922) group. 
Correlational analysis  
Duration of illness: Duration of illness was not correlated with cVV for 
either the Est-SZ (df= 84, p=.343) or FEP (df= 156, p=.583) group.  
 
DISCUSSION 
This study confirms that patients with established SZ have significantly 
enlarged ventricles (36.2%) compared to HCs. We found no statistically 
significant differences in cVVs between healthy controls and the FEP or UHR 
patients (irrespective of transition status), or any of the diagnostic sub-groups. 
However, our linear trend analysis showed that for those individuals with a 
schizophrenia presentation (i.e. schizophreniform or schizophrenia disorder), 
there was an increase in cVVs between groups, which corresponded to 
advancing stages of the illness (i.e. UHR-SZ < FEP-SZform < FE-SZ < Est-
Ventricle volumes in emerging psychotic disorders Berger G, et al. 
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SZ). Further, this analysis showed that patients with chronic schizophrenia 
and patients with FE schizophrenia had significant VE compared with UHR 
who subsequently developed schizophrenia. The chronic schizophrenia group 
also displayed VE in comparison to FE schizophreniform disorder. Thus, our 
study provides evidence that no marked VE is present during the earliest 
illness stages (i.e. UHR and FEP), but that the onset of psychosis may be the 
time point where the ventricles begin to enlarge and progress for those who 
go on to develop schizophrenia specifically, although the timing of VE cannot 
be clarified from our data.   
As expected, Est-SZ participants had cVVs that were significantly 
larger than HCs, which is consistent with the literature in this area (Pantelis et 
al., 2005; Kempton et al., 2010). However, we unexpectedly found that cVVs 
in the FEP group did not differ significantly from HCs, despite our large 
sample size (N=162). Worth noting, our FEP subgroup that met criteria for 
schizophrenia (N=46) had a mean VE of 18.5% relative to HCs (Cohen’s d= -
.443), which, though non-significant (p=0.153), is in line with two recent meta-
analyses of VVs in first-episode schizophrenia (Steen et al., 2006; Vita et al., 
2006). Thus, we may have been underpowered to detect significant 
differences in this specific subgroup [post-hoc power analysis suggests that 
we had 80% power to detect a medium effect size (i.e. f=0.245) when 
comparing the FEP-SZ group to the HC group; G*Power v3.1.3]. These meta-
analyses, which found small to moderate effects [e.g. composite d ranged 
from -.323 to -.608 (Vita et al., 2006)] with large samples (N=200+ patients) 
and comprised primarily of FEP individuals with schizophrenia-spectrum 
disorders, are further supported by our linear trend findings and implicates VE 
as being specific to an outcome diagnosis of schizophrenia. An alternative 
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explanation for the lack of VE in our FEP sample may be related to the 
characteristics of the sample differing to those of previous studies. In 
particular, our FEP patients were help-seeking and enrolled in a specialised 
early psychosis service and it is possible they were higher functioning than 
other previous FEP sample populations. However, as implied by the mean 
PANSS psychopathology scores of our FEP group (M=85.43, SD=17.73), 
which is considered to be in the ‘markedly to severely ill’ range (Leucht et al., 
2005), and which was not statistically different to our Est-SZ group, severity of 
overall symptomatology is less likely an explanatory factor. Future research 
should examine the direct and indirect relationships between symptom 
severity, general functioning and VVs across illness stages. 
Our finding that the UHR group, irrespective of transition status, 
displayed no VE, is in line with the majority of previous research conducted in 
genetic and clinical high-risk populations (Cannon et al., 1998; Lawrie et al., 
1999; Lawrie et al., 2001; Lawrie et al., 2002; Ziermans et al., 2009). The 
mean percentage difference in cVV for our UHR groups are intriguing, in 
particular for our UHR-SZ group (-18.5%), as cVVs tended to be reduced 
relative to HCs (see Figure 2). While this was a non-significant numerical 
difference, there appeared to be a small effect (Cohen’s d=.330). We assume 
that we were underpowered with an N of only 26 in this UHR subgroup. 
Nonetheless, a speculative explanation of reduced VV could be that during 
the schizophrenia prodrome, cells and tissue of the periventricular area 
undergo subtle swelling (von Hohenberg et al., 2014), which may potentially 
be the result of an active neurochemical or immunological process, such as 
neuroinflammation and/or neurotoxicity (Cropley et al., 2013; Cropley and 
Pantelis, 2014; Pantelis et al., 2005). To speculate further, a putative 
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inflammatory or immune response may be illness stage-specific, as there was 
no trend for reduced VVs in our FEP sample. We have recently theorized that 
swelling may be an initial response to an acute stressor during the prodromal 
phase, a phase associated with hyperdopaminergic and hyperglutamatergic 
state (Schobel et al., 2013), which may subsequently lead to excessive 
cortical grey matter loss following transition to psychosis. Furthermore, a 
recent study of increased niacin sensitivity in adolescents at UHR for 
psychosis is suggestive that the UHR state may be associated with a  “pro- 
inflammatory state”, whereas most niacin studies in established schizophrenia 
presents with impaired niacin sensitivity (Berger et al., 2016). Further 
research with a larger sample is needed to determine whether dynamic 
changes in brain volume (including swelling) are associated with changes in 
VVs in the context of psychosis onset and/or exacerbation (Cropley et al., 
2013; Cropley and Pantelis, 2014).  
An alternative explanation for the lack of significant group differences 
for our (and other) UHR samples may relate to the heterogeneity of this 
population. It is well known that there is great variability in terms of illness 
course in UHR, with a significant proportion of individuals never developing a 
psychotic illness (about two-thirds) and/or going on to have poor outcomes in 
general. In terms of VVs, the SD from the mean was large in our UHR group/s 
(although comparable to previous UHR research (Ziermans et al., 2009)), 
further suggestive of within-group diversity. It may be that VE is associated 
with only a sub-type within the schizophrenia-spectrum population, which may 
be dependent on the presence of one or several unknown genetic, 
neurobiological and/or environmental factors, and it may be that these factors 
were more prevalent in our Est-SZ group. However, given that within-group 
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variation of cVV in our UHR (and FEP) groups was not larger relative to our 
Est-SZ group (which in turn is comparable to previous research in Est-SZ 
(Nopoulos et al., 1997)), the overall evidence suggests VE is more likely a 
consequence of illness progression than a pre-existing condition for a sub-
group of individuals. Longitudinal research is needed to not only identify the 
precipitators, mediators/moderators and underlying mechanisms that drive VV 
changes, but to elucidate the timing of VV change. In the initial cross-sectional 
comparison study by Ziermans et al. (2009) mean VVs between converters 
and non-converters did not differ, but over a subsequent two-year follow up 
those who progressed to a first psychotic episode (UHR-P) showed a small 
but significant VE that was not seen in the group that did not convert to 
psychosis (UHR-NP; Ziermans et al., 2012). Cannon and colleagues (2015) 
similarly found no baseline group differences in VV, however over the 1 year 
follow-up the UHR-P group showed significantly greater expansion of the third 
ventricle than the UHR-NP and control groups. 
 Limitations of this study relate to the effects of medication and the 
impact of duration of illness. The analyses in our study are consistent with the 
notion of a somewhat differential effect of typical versus atypical 
antipsychotics on brain structure over time (Lieberman et al., 2005; Ansell et 
al., 2014), although our analyses are confounded by differences in duration of 
illness across these medication types; i.e. patients with chronic schizophrenia 
were more likely to be on typical antipsychotics or to have been treated with 
such drugs over a long period (such data were not available for analysis). As 
with our main analyses, we may have been underpowered to detect 
significant effects of atypical antipsychotics on VV, as the debate regarding 
the putative protective vs. damaging effects of these second generation 
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antipsychotics on the brain, especially over long time periods, is very much 
ongoing (Ho et al., 2011; Lieberman et al., 2005; Lesh et al., 2015). Contrary 
to our expectation, we did not find a relationship between duration of illness 
and cVV for either the FEP or Est-SZ groups. This suggests that VV change 
may not be associated with time as an independent factor (i.e. it does not 
accelerate at a constant rate), but potentially with time as a function of illness 
progression, implying that VV changes may be illness stage specific where 
volume loss progression occurs in unison with diagnostic/behavioural illness 
progression (Bartholomeusz et al., 2016; McGorry et al., 2014). 
Notwithstanding this, it is also possible that this result was confounded due to 
high colinearity between duration of illness and our covariate age, which were 
strongly and significantly correlated (Pearson’s r= .82, p<.001). Further, 
information on duration of untreated psychosis was not available, which may 
be relevant to VE, as suggested by others (Keshavan et al., 1998). Further, 
while we included sex (and age) as covariates in our analyses, males were 
overrepresented in our Est-SZ sample, and evidence suggests that VE may 
be more pronounced in this demographic group (Nopoulos et al., 1997).  
We also did not examine the impact of comorbid illnesses, which may 
have confounded our VV findings given that comorbidity, especially 
depression and anxiety disorders, tend to be highly prevalent in emerging 
psychosis (Sonmez et al., 2014; Cotton et al., 2012), including in this UHR 
sample (Lin et al., 2015). Indeed, meta-analysis shows that individuals with 
major depressive disorder or bipolar affective disorder, display significant VE 
in comparison to healthy controls (Kempton et al., 2011). Despite this, an 
earlier meta-analysis that directly compared individuals with bipolar disorder 
(considered by some researchers to be analogous to psychotic illness) to 
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schizophrenia patients, suggested that VE is significantly more pronounced in 
Est-SZ (Arnone et al., 2009). Thus, further research into the specificity of VE 
is needed (for discussion see Bartholomeusz and Pantelis, (in press)). 
This was a cross-sectional study, which did not allow for consideration 
of confounding factors (e.g., pharmacological treatments/psychosocial 
interventions) that may have impacted on illness outcomes, in particular 
transition status for our UHR sample post baseline assessment. As mentioned 
above, longitudinal designs, with multiple scan time-points and which are 
initiated from the earliest possible pre illness-onset stage, are needed 
(Bartholomeusz et al., 2016). Lastly, while we found no site-specific difference 
in ICV, and potential scanner-related variability across groups was expected 
to be similar (given participants from all groups were recruited and assessed 
over the whole period of data collection, including the control participants), 
there are possible scanner-related variations that were unaccounted for. 
Concluding Remarks 
The findings in this study suggest that VE is not a feature of the earliest 
stages of psychosis and schizophrenia (immediately preceding and 
immediately after psychosis onset), rather it is most apparent in patients with 
established schizophrenia. In light of the Royal Australian and New Zealand 
College of Psychiatrists adopting a clinical staging framework for 
recommending guidelines in clinical practice (Galletly et al., 2016), it is 
possible that the discovery of stage-specific neurobiological anomalies may 
aid in guiding treatment in the future. This would be particularly useful for the 
UHR syndromes and FEP stage of illness, where diagnosis and prognosis 
can be more difficult to determine clinically. Future work in this area should 
concentrate on long-term outcomes, the impact of episodes of illness 
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exacerbation and remission (Cropley et al., 2013; Cropley and Pantelis, 
2014), and examining the role of inflammatory markers (Berger et al., 2016) 
and the potential effects of neuroprotective agents (Berger et al., 2007; Berger 
et al., 2012). 
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Figure Legends 
 
Figure 1. ICV-corrected mean ventricular volumes (mm3) and mean 
standard error for the main illness groups (Analysis 1). Cross-sectional 
univariate ANCOVA showed a significant Group effect (p<.001). 
Pairwise comparisons with bonferroni correction found that the 
Chronic SZ group had significantly larger lateral ventricles than healthy 
control participants (*p<.001). 
Figure 2. Percentage of ventricular volume difference relative to healthy 
controls for each subgroup. Cross-sectional analysis of schizophrenia 
spectrum diagnoses subgroups revealed a significant linear trend from UHR 
to chronic schizophrenia (p<.01), whereby log transformed ventricular 
volumes (ICV corrected) increased with each schizophrenia illness stage 
(note: percentage difference relative to controls is shown for interpretation 
purposes; see supplementary material for graphical depiction of ICV-corrected 
VV [mm3] means and mean standard error for all subgroups). *p<.05, **p<.01 
for post hoc pairwise comparisons with bonferroni correction. 
 
